Table 3 Safety analysis in the combined with anti-angiogenosis group.

From: High endothelial venules predict response to PD-1 inhibitors combined with anti-angiogenesis therapy in NSCLC

AEs

Grade 1–2

Grade 3–4

Leukopenia

23 (24.0)

–

Thrombocytopenia

37 (38.5)

5 (5.2)

Nausea and vomiting

6 (6.2)

–

Diarrhea or constipation

11 (11.5)

2 (2.1)

Fatigue

44 (45.8)

–

Hypertension

13 (13.5)

–

Bleeding

9 (9.4)

–

Rash

8 (8.3)

1(1.0)

Hand-foot syndrome

12 (12.5)

–

Pneumonia

7 (7.3)

1 (1.0)

Back to article page